Brokers Offer Predictions for Delcath Systems Q1 Earnings

Key Points

• HC Wainwright revised its Q1 2026 earnings per share estimate for Delcath Systems down from $0.13 to $0.09, maintaining a "Buy" rating with a price target of $31.00.
• The company reported Q2 2026 expected earnings of $0.06 EPS and an overall fiscal outlook predicting growth to $2.55 EPS by FY2029.
• Delcath Systems' stock currently trades around $10.06, and hedge funds and institutional investors control 61.12% of the company's shares, indicating significant interest in the stock.

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 EPS estimates for Delcath Systems in a research note issued on Thursday, August 7th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.09 for the quarter, down from their prior estimate of $0.13. HC Wainwright currently has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems' Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.27 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $2.02 EPS and FY2029 earnings at $2.55 EPS.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.05. Delcath Systems had a net margin of 3.18% and a return on equity of 8.63%. The firm had revenue of $24.16 million for the quarter, compared to analysts' expectations of $22.84 million.

Other equities analysts have also recently issued research reports about the stock. Stephens reissued an "overweight" rating and issued a $25.00 price target on shares of Delcath Systems in a research note on Monday, June 23rd. Wall Street Zen upgraded shares of Delcath Systems from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Delcath Systems has a consensus rating of "Buy" and an average price target of $24.50.

Delcath Systems Stock Performance

Delcath Systems stock traded down $0.13 during midday trading on Friday, reaching $10.06. 132,421 shares of the stock were exchanged, compared to its average volume of 573,181. The company's fifty day moving average is $13.08 and its 200-day moving average is $13.64. The firm has a market cap of $350.42 million, a PE ratio of 201.80 and a beta of 0.82. Delcath Systems has a 52 week low of $7.17 and a 52 week high of $18.23.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors and hedge funds have recently made changes to their positions in DCTH. Soleus Capital Management L.P. bought a new stake in Delcath Systems in the 4th quarter valued at $9,644,000. Vivo Capital LLC boosted its stake in shares of Delcath Systems by 71.4% during the 4th quarter. Vivo Capital LLC now owns 1,708,579 shares of the company's stock worth $20,571,000 after purchasing an additional 711,574 shares during the period. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Delcath Systems during the 4th quarter worth about $7,371,000. Invesco Ltd. bought a new stake in Delcath Systems during the 1st quarter valued at about $5,084,000. Finally, Geode Capital Management LLC lifted its holdings in Delcath Systems by 128.1% during the 2nd quarter. Geode Capital Management LLC now owns 703,171 shares of the company's stock valued at $9,565,000 after buying an additional 394,902 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.